|
|
|
|
| LEADER |
00000cam a2200000Ia 4500 |
| 001 |
EBSCO_ocn832706789 |
| 003 |
OCoLC |
| 005 |
20231017213018.0 |
| 006 |
m o d |
| 007 |
cr cnu---unuuu |
| 008 |
130327s2012 nyu ob 001 0 eng d |
| 040 |
|
|
|a N$T
|b eng
|e pn
|c N$T
|d YDXCP
|d OCLCF
|d EBLCP
|d OCLCQ
|d D6H
|d VTS
|d TOF
|d AU@
|d STF
|d OCLCQ
|d K6U
|d OCLCO
|d OCLCQ
|d OCLCO
|
| 020 |
|
|
|a 9781621009610
|q (electronic bk.)
|
| 020 |
|
|
|a 1621009610
|q (electronic bk.)
|
| 020 |
|
|
|z 9781621009092
|
| 020 |
|
|
|z 1621009092
|
| 029 |
1 |
|
|a DEBBG
|b BV041049541
|
| 029 |
1 |
|
|a DEBBG
|b BV043775266
|
| 029 |
1 |
|
|a DEBSZ
|b 472777238
|
| 035 |
|
|
|a (OCoLC)832706789
|
| 050 |
|
4 |
|a RC46
|
| 072 |
|
7 |
|a HEA
|x 039000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 014000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 022000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 112000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 045000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 616
|2 23
|
| 049 |
|
|
|a UAMI
|
| 245 |
0 |
0 |
|a Advances in medicine & biology.
|n Volume 44 /
|c edited by Leon V. Berhardt.
|
| 260 |
|
|
|a Hauppauge, N.Y. :
|b Nova Science ;
|a Lancaster :
|b Gazelle [distributor],
|c 2012.
|
| 300 |
|
|
|a 1 online resource (xiv, 299 pages)
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 588 |
0 |
|
|a Print version record.
|
| 505 |
0 |
|
|a ADVANCES IN MEDICINE AND BIOLOGY ; ADVANCES IN MEDICINE AND BIOLOGY ; Contents; Preface; C. Elegans and Neurodegeneration in Caenorhabditis Elegans: Anatomy, Life Cycles and Biological Functions; 1. Introduction; 2. Alzheimer's Disease; Disease-Linked Mutations and Neurodegeneration; Screens Identifying Modifier Genes; Chemical- and Metal-Induced Neurodegeneration; Pharmacological Compounds and Neurodegeneration; 3. Parkinson's Disease; Disease-Linked Mutations and Neurodegeneration; Autosomal Dominant Genes; Autosomal Recessive Genes; Screens Identifying Modifier Genes.
|
| 505 |
8 |
|
|a Chemical- and Metal-Induced NeurodegenerationPharmacological Compounds and Neurodegeneration; 4. Huntington's Disease; Disease-Linked Mutations and Neurodegeneration; Expression of Isolated PolyQ; Expression of Htt N-Terminal Fragments; Screens Identifying Modifier Genes; Pharmacological Compounds and Neurodegeneration; 5. Amyotrophic Lateral Sclerosis (ALS); Disease-Linked Mutations and Neurodegeneration; Screens Identifying Modifier Genes; 6. Spinal Muscular Atrophy (SMA); Disease-Linked Mutations and Neurodegeneration; Screens Identifying Modifier Genes.
|
| 505 |
8 |
|
|a Pharmacological Compounds and NeurodegenerationConclusions; Acknowledgments; References; Caenorhabditis elegans as a Host Model for Studying the Pathogenicity and Virulence of Staphylococcus aureus; Abstract; Introduction; Staphylococcus aureus and MRSA; S. aureus Virulence and Pathogenicity; Animal Models for S. aureus; Biology of C. elegans; Worm Anatomy and Life Cycle; C. elegans Defense Mechanism; C. elegans as a Host Model for Studying Bacterial Pathogenesis; C. elegans as a Host Model for Studying S. aureus Pathogenesis.
|
| 505 |
8 |
|
|a The C. elegans Host Model Correlates with Clinical Manifestations of S. aureus Infections in a Large Canadian Health Care RegionMRSA Strains with Distinct Nematocidal Activities Have Different; Genetic Backgrounds; Validation of the C. elegans Model Using Canadian Major Epidemic; MRSA Strains; Validation of the C. elegans Host Model in a Neonatal Intensive Care Unit (NICU) Outbreak in Toronto; MSSA Strains with Distinct Nematocidal Activities Have Different Genetic Backgrounds; Accumulation of S. aureus inside the Digestive Tract Is Correlated with Nematocidal Activity.
|
| 505 |
8 |
|
|a S. aureus Lysozyme Resistance Contributes S. aureus Lysozyme Resistance ContributesA Lysozyme-Sensitive S. aureus Mutant Exhibited Reduced Accumulation inside the C. elegans Gut; Mutation of Lysozyme Genes in C. elegans Reduced Nematodes Fitness against S. aureus; Conclusion; References; Understanding the Molecular Basis for the Hazards Associated with Nevirapine Treatment; Abstract; Overview; Nevirapine Pharmacokinetics and Metabolism; Nevirapine Toxicity; Nevirapine Bioactivation; Synthetic Biomarkers as Tools for Biomonitoring Nevirapine Toxicity; Acknowledgments; References.
|
| 590 |
|
|
|a eBooks on EBSCOhost
|b EBSCO eBook Subscription Academic Collection - Worldwide
|
| 650 |
|
0 |
|a Clinical medicine.
|
| 650 |
|
0 |
|a Biology.
|
| 650 |
|
2 |
|a Clinical Medicine
|
| 650 |
|
2 |
|a Biology
|
| 650 |
|
6 |
|a Médecine clinique.
|
| 650 |
|
6 |
|a Biologie.
|
| 650 |
|
7 |
|a biology.
|2 aat
|
| 650 |
|
7 |
|a HEALTH & FITNESS
|x Diseases
|x General.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Clinical Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Diseases.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Evidence-Based Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Internal Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a Biology
|2 fast
|
| 650 |
|
7 |
|a Clinical medicine
|2 fast
|
| 700 |
1 |
|
|a Berhardt, Leon V.
|
| 776 |
0 |
8 |
|i Print version:
|t Advances in medicine & biology. Volume 44.
|d Hauppauge, N.Y. : Nova Science ; Lancaster : Gazelle [distributor], 2012
|z 9781621009092
|w (OCoLC)775029473
|
| 856 |
4 |
0 |
|u https://ebsco.uam.elogim.com/login.aspx?direct=true&scope=site&db=nlebk&AN=535149
|z Texto completo
|
| 938 |
|
|
|a ProQuest Ebook Central
|b EBLB
|n EBL3021363
|
| 938 |
|
|
|a EBSCOhost
|b EBSC
|n 535149
|
| 938 |
|
|
|a YBP Library Services
|b YANK
|n 7245546
|
| 994 |
|
|
|a 92
|b IZTAP
|
